徵求以下兩篇文獻,謝謝板上前輩的協助!!!
J Med Econ. 2016 Apr 20:1-8. [Epub ahead of print]
Cost per median overall survival month associated with abiraterone acetate
and enzalutamide for treatment of patients with metastatic
castration-resistant prostate cancer.
Expert Opin Pharmacother. 2015 Mar;16(4):473-85. doi:
10.1517/14656566.2015.995090. Epub 2014 Dec 23.
Enzalutamide versus abiraterone acetate for the treatment of men with
metastatic castration-resistant prostate cancer.
請寄到timchen2117@gmail.com
謝謝!!!